Plus Therapeutics (NASDAQ:CNSY) Announces Earnings Results, Misses Estimates By $0.16 EPS

Plus Therapeutics (NASDAQ:CNSY) released its quarterly earnings results on Friday. The company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.16), FiscalAI reports. The business had revenue of $0.72 million during the quarter. Plus Therapeutics had a negative return on equity of 394.17% and a negative net margin of 620.70%.

Plus Therapeutics Stock Up 23.3%

Shares of Plus Therapeutics stock traded up $0.18 during mid-day trading on Friday, reaching $0.95. 8,046,110 shares of the stock traded hands, compared to its average volume of 1,810,277. The stock has a market capitalization of $7.21 million, a PE ratio of -0.28 and a beta of 1.49. The company has a 50-day moving average price of $1.70. Plus Therapeutics has a fifty-two week low of $0.43 and a fifty-two week high of $18.89.

Analyst Upgrades and Downgrades

CNSY has been the subject of a number of recent analyst reports. Zacks Research upgraded Plus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Monday, November 2nd. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Plus Therapeutics has an average rating of “Reduce”.

Plus Therapeutics Company Profile

Plus Therapeutics is a clinical-stage biopharmaceutical company developing targeted radiotherapeutics for cancers of the central nervous system. The company is based in Austin, Texas, and was formerly known as Cytori Therapeutics. Its lead investigational product, REYOBIQ (rhenium-186 obisbemeda), is designed to deliver radiation directly to tumors in the brain and central nervous system. The treatment is being studied for conditions including recurrent glioblastoma and leptomeningeal metastases.